Colin Kosse's questions to Apellis Pharmaceuticals Inc (APLS) leadership • Q1 2025
Question
Colin Kosse asked about the perceived risk of the third-party co-pay assistance programs not being refunded and potentially going away completely.
Answer
Executive David Acheson responded that the situation is unpredictable. He stated that Apellis is operating under the assumption that the funding will not return. Consequently, the company anticipates sample usage will remain elevated, and its strategy is focused on managing the balance between sample and commercial doses.